A novel double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]tofogliflozin after oral administration and concomitant intravenous microdose administration of [ 13C]tofogliflozin in humans

Clinical Pharmacokinetics

Volumn 52, Issue 6, 2013, Pages 463-473

  Schwab, Dietmar ^a   Portron, Agnes ^a   Backholer, Zoe ^a   Lausecker, Berthold ^a   Kawashima, Kosuke ^b  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

TOFOGLIFLOZIN C 12; TOFOGLIFLOZIN C 13; TOFOGLIFLOZIN C 14; TRACER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY CLEARANCE; KIDNEY TUBULE EXCRETION; LIQUID CHROMATOGRAPHY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RADIOACTIVITY; STEADY STATE; TANDEM MASS SPECTROMETRY; URINALYSIS;

ABSORPTION; ADMINISTRATION, ORAL; BENZHYDRYL COMPOUNDS; CARBON ISOTOPES; CARBON RADIOISOTOPES; DRUG MONITORING; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MOLECULAR STRUCTURE; SODIUM-GLUCOSE TRANSPORTER 2; TISSUE DISTRIBUTION;

EID: 84878738942     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-013-0051-z     Document Type: Article

References (28)

1. Suzuki M, Honda K, Fukazawa M, Ozawa K, Hagita H, Kawai T, et al. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther. 2012;341(3):692-701.
2. Ikeda S, Takano Y, Cynshi O, Christ AD, Boerlin V, Beyer U, Beck A. A novel and selective SGLT2 inhibitor, tofogliflozin improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus. In: European Association for the Study of Diabetes, annual meeting 2012, Berlin [abstract no. 768].
3. Schwab D, Portron A, Fukushima Y, Backholer Z, Kuhlmann O, Saito T, Ikeda S. Tofogliflozin a selective SGLT2 inhibitor exhibits highly favourable drug properties for use in patients with renal impairment and for combination with other medicines. In: European Association for the Study of Diabetes, annual meeting 2012, Berlin [abstract no. 767].
4. +/d-glucose cotransporters SGLT1 and SGLT2. Am J Physiol Cell Physiol. 2011;300(1):C14-21.
5. Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 2009;75(12):1272-7.
6. Abdul-Ghani MA, DeFronzo RA. Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocr Pract. 2008;14(6):782-90.
7. Chao EC, Henry RR. SGLT2 inhibition - a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010;9(7):551-9.
8. ICH. International conference on harmonization of technical requirements for registration of pharmaceuticals for human use. ICH harmonized tripartite guideline. Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. M3(R2) Current Step 4 version dated 11 June 2009.
9. Lappin G, Garner RC. The utility of microdosing over the past 5 years. Expert Opin Drug Metab Toxicol. 2008;4(12):1499-506.
10. Lappin G, Kuhnz W, Jochemsen R, Kneer J, Chaudhary A, Oosterhuis B, et al. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. Clin Pharmacol Ther. 2006;80(3):203-15.
11. Lappin G, Rowland M, Garner RC. The use of isotopes in the determination of absolute bioavailability of drugs in humans. Expert Opin Drug Metab Toxicol. 2006;2(3):419-27.
12. Lappin G, Shishikura Y, Jochemsen R, Weaver RJ, Gesson C, Houston B, et al. Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. Eur J Pharm Sci. 2010;40(2):125-31.
13. Ni J, Ouyang H, Aiello M, Seto C, Borbridge L, Sakuma T, et al. Microdosing assessment to evaluate pharmacokinetics and drug metabolism in rats using liquid chromatography-tandem mass spectrometry. Pharm Res. 2008;25(7):1572-82.
14. Sparreboom A. Unexplored pharmacokinetic opportunities with microdosing in oncology. Clin Cancer Res. 2007;13(14):4033-4.
15. Sugiyama Y. Effective use of microdosing and positron emission tomography (PET) studies on new drug discovery and development. Drug Metab Pharmacokinet. 2009;24(2):127-9.
16. 14C-acetaminophen with accelerator mass spectrometry to examine pharmacokinetics of parent drug and metabolites in healthy subjects. Clin Pharmacol Ther. 2010;88(6):824-30.
17. 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers. J Clin Pharmacol. 2005;45(10):1198-205.
18. Outcomes from EUMAPP - a study comparing in vitro, in silico, microdose and pharmacological dose pharmacokinetics. In: European Microdosing AMS Partnership Programme (EUMAPP); 2009. http://www.eumapp.com/pdfs/ EUMAPP%20SUMMARY.pdf. Accessed 9 Nov 2012.
19. Rubin GM, Waschek JA, Pond SM, Effeney DJ, Tozer TN. Concurrent intravenous administration of a labeled tracer to determine the oral bioavailability of a drug exhibiting Michaelis-Menten metabolism. J Pharmacokinet Biopharm. 1987;15(6):615-31.
20. Maeda K, Sugiyama Y. Novel strategies for microdose studies using non-radiolabeled compounds. Adv Drug Deliv Rev. 2011;63(7):532-8.
21. Gu H, Wang J, Aubry AF, Jiang H, Zeng J, Easter J, et al. Calculation and mitigation of isotopic interferences in liquid chromatography-mass spectrometry/mass spectrometry assays and its application in supporting microdose absolute bioavailability studies. Anal Chem. 2012;84(11):4844-50.
22. Gibaldi M, Perrier D. Pharmacokinetics. Noncompartmental analysis based on statistical moment theory. 2nd ed., revised and expanded ed. New York: Marcel Dekker; 1982.
23. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function - measured and estimated glomerular filtration rate. N Engl J Med. 2006;354:2473-83.
24. Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med. 1916;17:863-71.
25. Penner N, Klunk LJ, Prakash C. Human radiolabeled mass balance studies: objectives, utilities and limitations. Biopharm Drug Dispos. 2009;30(4):185-203.
26. Roffey SJ, Obach RS, Gedge JI, Smith DA. What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab Rev. 2007;39(1):17-43.
27. Zhang Y, Zhang L, Abraham S, Apparaju S, Wu T-C, Strong JM, Xiao S, Atkinson AJ Jr, Thummel KE, Leeder JS, Lee C, Burckart GJ, Lesko LJ, Huang S-M. Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications. Clin Pharm Ther. 2009;85(3):305-11.
28. Rowland Yeo K, Aarabi M, Jamei M, Rostami-Hodjegan A. Modeling and predicting drug pharmacokinetics in patients with renal impairment. Expert Rev Clin Pharmacol. 2011;4(2):261-74.